Table 2.
Baseline prognosis factors for overall survival.
| Variables | No. | Univariate Analysis | Multivariate Analysis | Hazard Ratio | 95% CI |
|---|---|---|---|---|---|
| CTC count | |||||
| CTC < 5 | 23 | 0.001 | 0.002 | 3.24 | 1.2–4.3 |
| CTC ≥ 5 | 37 | ||||
| CTC-EGFR | |||||
| (−) | 45 | <0.001 | <0.001 | 4.01 | 1.1–6.8 |
| (+) | 15 | ||||
| PSA (ng/mL) | |||||
| <30 | 30 | 0.015 | 0.053 | 4.01 | 1.1–6.8 |
| ≥30 | 30 | ||||
| Biopsy Gleason score | |||||
| 7–8 | 29 | 0.011 | 0.42 | 1.02 | 0.6–2.9 |
| 9–10 | 31 | ||||
| EOD | |||||
| 1–2 | 39 | 0.012 | 0.285 | 1.49 | 0.5–6.8 |
| 3–4 | 21 | ||||
| Hemoglobin (g/dL) | |||||
| <11.5 | 35 | 0.028 | 0.247 | 1.11 | 0.6–5.6 |
| ≥11.5 | 25 | ||||
| Serum albumin (g/dL) | |||||
| <3.7 | 38 | 0.029 | 0.312 | 1.08 | 0.7–5.9 |
| ≥3.7 | 22 | ||||
| Alkaline phosphatase (IU/L) | |||||
| <313 | 21 | 0.003 | 0.017 | 2.46 | 1.2-5.3 |
| ≥313 | 39 | ||||
| Lactate dehydrogenase (IU/L) | |||||
| <226 | 26 | 0.008 | 0.121 | 1.9 | 0.5–2.9 |
| ≥226 | 34 | ||||
| Disease involvement | |||||
| Only bone | 42 | 0.071 | 0.226 | 1.17 | 0.6–2.4 |
| Bone plus node | 18 | ||||
The extent of bone metastasis was classified by the extent of disease (EOD) grade.